MMC Healthcare · PDF fileMMC Healthcare Ltd (MMC) was founded by four ... Hemocare, Combit,...
Transcript of MMC Healthcare · PDF fileMMC Healthcare Ltd (MMC) was founded by four ... Hemocare, Combit,...
MMC Healthcare Ltd(WHO – GMP & ISO 9001: 2008 certified company)
C P iCorporate Presentation
November 2014
Scheme of presentation2
Industry overview
About the company
Milestonesn Milestones
Infrastructure
rate Presentatio
Key strengthsCorpor
2014
Global Pharmaceutical Industry ‐ Overview 3
l b l h kIMS institute estimates that Global Pharmaceutical Industry to be US$ 956 Bn in 2011 and is estimated to grow at CAGR of 3‐6% during 2012 – 16. U.S (US$ 322 B ) f ll d b EU 5 (US$159 B ) th j
34%2%
15%United States
Rest of the world
Global Pharma Market in 2011
322 Bn) followed by EU 5 (US$159 Bn) are the major markets that contributes to about 50% of the global market.
The term “Pharmerging” market was coined by IMSn 17%
20%
States
Pharmerging
Canada
The term Pharmerging market was coined by IMS to signify the growing shift of growth momentum to emerging markets that includes Brazil, Russia,Indiaand China (BRIC). These markets are expected to hi CAGR f 12 15% i t th t f 1 4% fra
te Presentatio 17%
12%EU 5
Japan
Therapy Areas Market Size (US$ Bn)
Top 10 therapy areas projections ‐ 2016
achieve a CAGR of 12‐15% against that of 1‐4% of developed markets during 2012 ‐16.
China leads the pack as Tier 1 market, is estimated to have a pharmaceutical spending of US$ 155 to
Corpor Therapy Areas Market Size (US$ Bn)
Oncologics 83 – 88
Antidiabetics 48 – 53
Asthma/COPD 44 – 48to have a pharmaceutical spending of US$ 155 to US$ 165 Bn by 2016.
Brazil, Russia, India put together as Tier 2 markets follows China and is expected to become a 100 – 110
Autoimmune 33 – 36
Lipid Regulators 31 – 34
Angiotensin II 22 – 25
HIV Antivirals 22 – 25
market by 2016.
2014Source: IMS institute report
Antipsychotics 22 – 25
Vaccines 19 – 22
Immunostimulants 16 – 18
Indian Pharmaceutical Industry ‐ Overview 4
k h b l hIndian Pharmaceutical market is estimated to be at US$ 21 Bn in 2014 growing at annual growth rate of 13%. It ranks 3rd in volume and 14th value terms of
f t i f h d t l b ll
13%
10%
Mkt share by value ‐ therapy areas (2014)
Alimentary
manufacturing of pharma products globally.
India produces about 20% ‐ 24% of the global generic drug production. The generic market is expected to explode with about US$ 60 bn expiredn
10%
9%
6%59%
Cardiovascular
Respiratory
expected to explode with about US$ 60 bn expired in 2012. Along with the opportunity offered by patent expired in 2007, the newly available market is estimated to be about US$ 73 Bn.
rate Presentatio
6%3%Other therapeutic
areasCentral Nervous
Oncology
Relative cost of production(US cost base)Indian industry’s export is estimated to double by reaching about US$ 18.2 Bn by 2016 from value of US$ 12 bn in 2014
Indian pharmaceutical market is estimated to grow
Corpor Relative cost of production(US cost base)
US 100Indian pharmaceutical market is estimated to grow at a CAGR of about 17% to reach US$ 35.9Bn by 2016. The domestic market could be broadly classified into API, CRAMS, Formulations and
Europe
India
85
40Biosimiliars.
2014Source: IBEF report, FICCI Pharma report, Pharmabiz portal
India 40
Indian Pharmaceutical Market ‐ Major Market Segments
5
• Country boast a world class manufacturing infrastructure with about 161 USFDA, 90 MHRA, and 1,000 WHO GMP approved plants.
India is poised to replace Italy to become second largest supplier of APIs to globalAPI
n
India is poised to replace Italy to become second largest supplier of APIs to global pharma industry.The addressable export market estimated to be about US$ 8.7 Bn
CRAMS
rate Presentatio Indian CRAMS market was estimated to be US$ 3.8 Bn in 2010, accounting for just
6% of US$ 67 Bn global outsourcing market. Contract Manufacturing Operations (CMO) has dominated the market with about US$ 2.3 Bn in size.
CRAMS
Corpor
The prescription and OTC market constitute the domestic formulations market. It is estimated to be about US$ 10 Bn and is expected to achieve double digit gro th dri en b co ntr ’s strong economic and demographic f ndamentals
Formulations
growth driven by country’s strong economic and demographic fundamentals
Indian Biosimiliars is estimated to be of US$ 338 Mn in 2010 and is estimated to have reached US$ 580 Mn in 2012.
Biosimiliars
2014
The market is expected to explode by 2015 when US$ 79 Bn worth of biologicals is expected to go off patent.
Source: IBEF , CARE, ICRA reports MMC Healthcare has presence in these segments
Company Overview6
MMC Healthcare Ltd (MMC) was founded by four pharmaceutical professionals (alumni of Madurai Medical College), in 1987 as a partnership firm and was converted in to a closely held public limited company in 1997. 4.66%
1.63% 1.62%3.65%
Sales by therapy areas
Others
Dermatology Pediatrics
to a closely held public limited company in 1997.
The company’s major focus is into domestic branded formulation market (US$ 10 Bn Market size in 2010) serving the therapy areas viz., Gynecology, Orthopedics, Surgery and General Medicine etcn 63 78
19.82
4.85%Surgery
Ortho
and General Medicine etc.,
A wide product profile of about 50 branded formulations promoted by dedicated field force of 205 Medical representatives guided by about 58 Managers at various levels The field force reaches out to about 32 000 doctorsra
te Presentatio
cove
63.78%
%
Revenue growth Rs. In Cr
PhysiciansGynecology
levels. The field force reaches out to about 32,000 doctors.
Company’s export division caters to 14 countries and has applied for registration of products in 17 new countries
Wellness division was launched in 2009 by launching Noni
Corpor cove
41.23
42.00
41
42
43
based herbal drink AbleTo , later converted to Ethical Marketing.
MMC is actively exploring herbal medicine market and geriatric segment for expansion.
38.47
37
38
39
40
41
g g p
The company is actively exploring options for strategic alliances like Co marketing of brands to expand its national presence2014
36
37
FY 12 FY 13 FY 14
Contract Manufacturing – Himachal Pradesh Unit7
MMC undertakes contract manufacturing as a part of its business model. In 2005, the promoters expanded the business by setting up an exclusive unit in Himachal Pradesh held by an Special
22%
Sales of MMC HP unit by clients
Purpose Vehicle (SPV), MMC Healthcare (HP) Ltd.,The unit clocked a revenue of about Rs.21 Cr in FY 14.Company’s prestigious clientele includes Cipla, Lupin, Medopharm, Pharmed, Medispan etc.,n
MMC Healthcare Ltd
OtherMMC intends to become a full fledged Contract Research and Manufacturing Services (CRAMS) player by foraying into formulation R&D.During 18th & 19th July, MMC participated in Pharmac South ra
te Presentatio
Revenue growth Rs. In Cr
78%Other Clients
2014 organized by IDMA TNPSB as Exhibitor. Through this exhibition, MMC has genarated large number of new customers & expecting to bag to orders.Fiscical incentives for this plant is ending as on May 2015. Th f MMC h i d th it t Hi h l
Corpor
41.2342.00
41
42
43
Therefore MMC has acquired another unit at Himachal Pradesh for the purpose of extending excise benefits. This unit will be operated as a subsidiary of MMC . This move will help MMC to boost a top line growth of approximately 18 – 20 crores from 2015‐16 onwards.
38.47
36
37
38
39
40
18 20 crores from 2015 16 onwards.
2014
36
FY 12 FY 13 FY 14
Milestones8
MMC celebrated its 25 years of successful presence in Indian pharmaceutical industry in 2012 and is marching ahead with growth plans to propel itself to next orbit of growth.
Obtained ISO Geographic
n
WHO – GMP approval for the plant
Inauguration of an l i l i
Obtained ISO 9001:2000 certification
Inauguration of new t ffi
Launch of Wellness division
Geographic expansion drive
Converted as public li it dra
te Presentatio exclusive plant in
Himachal Pradesh for Contract Manufacturing
corporate office
limited company
Corpor
Product expansion drive
Acquired new unit Trimurti at Himachal
1997
Reconstruction of Chennai plant
Training centre for employees inaugurated
Kick started exports
expansion drivePradesh
2014
Incorporated as a partnership company
p
Key Management Profile9
Company is run by the founding team, who are equipped with about three decades of experience in the various faculties of Pharmaceutical Industry
Supported by long standing, experienced employee base, the company is now set for the next phase of growth and is aggressively expanding the management team.
n
Mr. M. Ravichandran, Director – ProductionHe holds a bachelor of pharmacy degree. He heads the company's production operations in two plants with 30 Years experience in pharmaceutical field He is also an Executive committee member
rate Presentatio plants with 30 Years experience in pharmaceutical field. He is also an Executive committee member
of Himachal Pradesh Drug Manufacturers Association and Executive committee member of Confederation of Indian Pharmaceutical Industry.
Mr. R.S. Jayaraman, Director – Exports
Corpor He holds a bachelor of pharmacy degree. He has vast international business experience in
pharmaceutical field. His area of expertise includes indenting and Sourcing for pharmaceutical global businesses.
j hi i k i & iMr. M. Rajarathinam , Director – Marketing & FinanceHe holds a bachelor of pharmacy degree and he has a vast experience in the field of pharma sales and marketing. He heads MMC's strong marketing force and is the man behind the company's innovative and dynamic marketing strategies. He also heads the company's finance operations. He Is Holding The Position Of Chairman Of Indian Drug Manufacturers Association, Tamilnadu State Board
2014
g g ,and Executive Committee member of Pharmaceutical Manufacturers Association, Tamilnadu and a Special invitee for IDMA, Mumbai. Under his leadership, on July 18th & 19th , IDMA TNPSB had very sussefully conducted Pharmac South 2014 at Chennai, which was appreciated by industry & has expanded the reach for the company.
Succession Plan10
Mr. Subash Vallab
n
Holds a Commerce and Management degree & undergoing
Diploma in Pharmaceutical strategy management. Immediately
f l i j i d Al bi h ( ll I di k 2 )
rate Presentatio after completion, joined Alembic pharma (all India Rank 25) as
Medical Representative in Trichy HQ in Cardiac Diabetic division
to practically understand pharmaceutical selling. Then he moved
Corpor
p y p g
to Mumbai and worked in Sales administration in Mumbai based
Tidal laboratories. In April’14 he joined MMC as a Management
Trainee and presently been assigned to create / update SOP in all
department of MMC
2014
Product Profile11
MMC produces and markets products in 10 therapeutic segments.
The major focus is on four segments namely Gynecology, Orthopedics, Surgery, and General Medicine.
n
Therapeutic Segment Key Brands
Hemocare group Nutritional Supplement ‐ Hematinics
Pileum group Alimentary System ‐ Hemorrhoids
Product Segment
rate Presentatio
Gynecology
Pileum group Alimentary System Hemorrhoids
Cystop Hormonal ‐Gynecology Specialty Product
Folibrain Baby’s brain development‐GynecologySpecialty Product
Corpor Specialty Product
Nausik, Calys, Argicare Gynec. specialty product, Calcium Supplement, Male infertility and fetal well being
AC group Musculo Skeletal System ‐Pain Management
Medicam group Musculo Skeletal System ‐ Pain Management
Cervispon Musculo Skeletal System ‐ Cervical Spinal
2014
OrthopedicsCervispon Musculo Skeletal System Cervical Spinal
Problems
DOM Z group, Calys Acid Peptic Disorders, Calcium Supplement
Product Profile12
Therapeutic Segment Key Brands Product Segment
Medineuron group Nutritional Supplement ‐ Neuritis
S tid E IPS P t l ti A ti I fl t
n
Septidase group, Enzo‐IPS plus
Proteolytic enzyme–Anti Inflammatory
AC group Musculo Skeletal System ‐Pain Management
DOM Z group Alimentary System Acid Peptic DisordersGeneral Medicine
rate Presentatio DOM Z group Alimentary System ‐Acid Peptic Disorders
Medicold Respiratory System
Ator4u Cardio Vascular System – Cholesterol Control
Corpor
Picolax group Alimentary System – Picolax group
Hemocare group Nutritional Supplement – Hematinics
Hemocare, Combit, Pileum Hematinics, Hair growth, Hemorrhoids
Surgery
Hemocare group Nutritional Supplement – Hematinics
Pileum group Alimentary System – Hemorrhoids
Medineuron group Nutritional Supplements ‐ Neuritis
2014
Combit, DOM Z, Moxodin, Cefodin
Hair growth, Acid peptic disorders, Anti Biotic
Product Profile13
ABLEto Complementary Therapy – Herbal health drink
Therapeutic Segment Key Brands Product Segment
n
Wellness
p y py
rate Presentatio
Delage Eye care ‐ Antioxidant
Corpor
Ophthalmology
EbMont Asthma & COPD
EbMont‐L Asthma & COPD
EbMont‐AL Asthma & COPD
2014
Respiratory
EbMont‐AL Asthma & COPD
Deflawin Asthma & COPD
Facilities14
MMC owns a WHO GMP, ISO 9001 – 2000 manufacturing facility at SIDCO Industrial Estate, in Thirumazhisai, Chennai.
Area: 18,073 Sq FtProduction Capacity: bl kh bl
n
Production Capacity: Tablets 250 Lakhs Tablets
Capsules 100 Lakhs Capsules
Liquids 1.25 Lakhs Litres
rate Presentatio
Thirumazhisai PlantDry Powders 3 Metric Tons
MMC healthcare (HP) Pvt Ltd., a group company of MMC owns a WHO GMP, ISO 9001 –2000 manufacturing facility at Solan in Himachal Pradesh. This unit mainly caters to
Corpor 2000 manufacturing facility at Solan in Himachal Pradesh. This unit mainly caters to
contract manufacturing businessArea: 32,000 Sq FtProduction Capacity:
Tablets 300 Lakhs TabletsTablets 300 Lakhs Tablets
Capsules 100 Lakhs Capsules
Liquids 1.25 Lakhs Litres
Dry Powders 3 Metric Tons
2014
Solan PlantDry Powders 3 Metric Tons
New acquisition: under construction
Domestic presence in branded formulations15
MMC boasts a 205 strong medical representatives and about 58 line managers at various levels covers about 32,600 doctors across the country, where it operates.Thi SBU t ib t t b t 60 % f th ’
Domestic Presence
This SBU contributes to about 60 % of the company’s sale. The company has a strong presence in South India with significant presence in Karnataka, Tamil Nadu, and Kerala with a share of 50% of overall sales.n and Kerala with a share of 50% of overall sales. Orissa, Chhattisgarh and Jharkhand in Eastern region also contribute about 23 % of the overall sales.Maharashtra has a share of 12% of the sales.MMC has entered Uttar Pradesh and Madhyara
te Presentatio
MMC has entered Uttar Pradesh and Madhya Pradesh recently & is planning to launch West Bengal & North‐east in 2015 to expand its national presence.The company also plans to become a pan India
i i b 17 18
Corpor
organization by year 17‐18.Company’s distribution network consists of 12 C&A agents and 520 stockists in the regions it operatesCompany is focusing on Respiratory (Physicians) & Gynec segmentGynec segment
2014
International Presence16
The company has registered 94 products in 14 countries and has applied for new product registrations of 136 products in 31 countries (Of which 17 countries are new geographical expansions). The new registrations are expected happen by early 2015.
R f t h i d b 160% i FY 14 d t th t f FY 13
n
Products Registered : 1
Ukraine
Products
Tajikistan
Revenue from exports have increased by 160% in FY 14 compared to that of FY 13.
rate Presentatio Under
Registration : 3
Products
Jordan
Registered : 3Under Registration: 4
Products
Algeria
Phili i
Corpor Registered: 3Registered : 1
Under Registration: 42
Francophone Under Registration :5
Philippines
D.R.Congo Maldives Sri Lanka
ProductsRegistered : 3 Under Registration: 13
Zambia
Under Registration :6
Vietnam
2014
Products Registered :2Under Registration : 0
Products Registered : 23Under Registration : 10
Products Registered : 18Under Registration : 7
Registration: 13
Awards and Clientele17
MMC healthcare ltd is affiliate d to leading industry body associations like IDMA, CII, FICCI, and Pharmexil etc.,
The company was recently awarded with “The Emerging
n
Company of the year” at Pharma excellence awards function in February 2013
rate Presentatio
The Emerging Company of the h l l l d
Corpor Year – February 2013The prestigious clientele includes
2014
Key Strengths18
Strong Management Team: Founded and managed by industry veterans equipped with about 3 decades of experience in various faculties of the pharmaceutical industry.
P i d b di i i f h i i i h i dPromoters represent industry bodies as a recognition of their expertise in the industry
Succession plan initiated already.
Good base in branded formulation market and geographical spread:n Good base in branded formulation market and geographical spread: Significant presence in South India
Markets above 50 branded formulations with dominant presence in 4 therapy segments.
rate Presentatio
Some of the key brands commanding good annual sales
> 6 crores – Hemocare
3‐6 crores – Medineuron & AC group
2 3 Pil
Corpor
2‐3 crores – Pileum
1‐2 crores – EbMont, COMBit, Cervispon, Medicam & Cystop
Product innovation: The company continues to differentiate itself through product innovations
2014
Key Strengths19
Intellectual Property:
Trade Mark: All MMC products have registered Brand Names conforming to the regulations of Trade Mark registration.
Patent registration: MMC has already submitted application for patency for the products PILEUM (Application no. 2644/CHE/2007) and COMBit (Application no. 2966/CHE/2009) with all the requisite details and awaiting the sanction of patency.
F th d t C i th li ti f t i t b b itt d i thn For another product Cureperium the application for patency is to be submitted in the near future.
Well laid out growth plans: Medium term outlook : Strategy 2014 – 15Th h l id t bl i t f b th di d l t th d ira
te Presentatio
The company has laid out a blue print for both medium and long term growth and is in the process of executing the plans
MMC looks for opportunities for Co marketing and alliances to expand its national foot print
Corpor
foot print
2014
Contact Information20
Contact
n
Mr. M. RajarathinamDirector – Marketing & Finance
rate Presentatio
Mob. No: + 91 9841047472Email: [email protected]
Corpor
Phone: 044‐24868412 / 8413, 2486 6348 / 6358Fax: 044 – 2486 6378Email: [email protected]: mmchealthcareindia.com
2014
Thank YouThank You2014 Corporate Presentation 21